Detection of Adverse Drug Reaction Signals in the Thai FDA Database: Comparison between Reporting Odds Ratio and Bayesian Confidence Propagation Neural Network Methods
Restricted accessOtherFirst published online July, 2010
Detection of Adverse Drug Reaction Signals in the Thai FDA Database: Comparison between Reporting Odds Ratio and Bayesian Confidence Propagation Neural Network Methods
The study aimed to compare performance between the reporting odds ratio (ROR) and the Bayesian confidence propagation neural network (BCPNN) methods in identifying serious adverse drug reactions (ADRs) using the Thai FDA spontaneous database. The two methods were retrospectively applied to identify new, serious ADRs reported with antiretroviral therapy (ART) drugs using the data set between 1990 and 2006. We plotted the ROR and the information component against time to compare the differential timing of signal detection and the pattern of signaling over time between these methods. The ROR and the BCPNN methods identified the associations between ART drugs and serious ADRs at the same time. Both methods were similar in detecting the first signal of a potential ADR. However, the pattern of signaling seems relatively different with each method. Additional analyses of different drugs, ADRs, and databases will contribute to increase understanding of methods for postmarketing surveillance using spontaneous reporting system.
PalellaFJJr.DelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med.1998;338: 853–860.
2.
CrumNFRiffenburghRHWegnerSComparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr.2006;41(2):194–200.
3.
SterneJACHernanMALedergerberBLong-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet.2005;366: 378–384.
4.
BartlettJAFathMJDeMasiRAn updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS.2006;20: 2051–2064.
5.
YazdanpanahYSissokoDEggerMMoutonYZwahlenMCheneG.Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ.2004;328: 249–255.
6.
CarrACooperD.Adverse effects of antiretroviral therapy. Lancet.2000;356: 1423–1430.
7.
FellayJLedergerberBBernasconiEPrevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet.2001;358: 1322–1327.
8.
SchillerD.Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health-Syst Pharm.2004;61: 2507–2522.
9.
MonforteAALepriACRezzaGInsights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS.2000;14: 499–507.
10.
AmmassariAMurriRPezzottiPSelf-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr.2001;28: 445–449.
11.
YuanYL'ItalienGMukherjeeJIloejeU.Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med.2006;7(3): 156–162.
12.
BissonGGrossRMillerVWellerIWalkerA.Monitoring of long-term toxicities of HIV treatmerits: an international perspective. AIDS.2003;17: 2407–2417.
13.
BateALindquistMEdwardsIROrreR.A data mining approach for signal detection and analysis. Drug Saf.2002;25: 393–397.
14.
ShakirSAW. Thoughts on signal detection in pharmacovigilance. Drug Saf.2007;30: 603–606.
15.
BateALindquistMEdwardsIRA Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol.1998;54: 315–321.
16.
EvansSJWWallerPCDavisS.Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf.2001;10: 483–486.
17.
EgbertsACGMeyboomRHBvan PuijenbroekEP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf.2002;25: 453–458.
18.
SzarfmanAMachadoSGO'NeillRT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf.2002;25: 381–392.
19.
EdwardsIRAronsonJK. Adverse drug reactions: definitions, diagnosis, and management. Lancet.2000;356: 1255–1259.
20.
WHO Collaborating Center for Drug Statistics Methodology. About the ATC/DDD system. http://www.whocc.no/atcddd/. Accessed October 20, 2008.
21.
WHO Collaborating Center for International Drug Monitoring: The Uppsala Monitoring Center.Concepts in critical terms. http://who-umc.org/DynPage.aspx?id=22686. Accessed October 20, 2008.
22.
van PuijenbroekEPDiemontWLvan GrootheestK.Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf.2003;26(5):293–301.
23.
Faculty of Pharmaceutical Science, Chulalongkorn University.Development of signal detection and assessment tool for the Thai FDA spontaneous reporting database. Bangkok; 2005.
24.
LindquistMStahlMBateAEdwardsIRMeyboomRHB. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf.2000;23: 533–542.
25.
LonerganJBehlingCPfanderHHassaneinTMathewsW.Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis.2000;31(1):162–166.
26.
JohnMMooreCBJamesIRChronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS.2001;15: 717–723.
27.
Arenas-PintoAGrantAEdwardsSWellerI.Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect.2003;79: 340–343.
28.
FalcoVRodriguezDRiberaESevere nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis.2002;34: 838–846.
29.
BoubakerKFleppMSudrePHyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect Dis.2001;33: 1931–1937.
30.
MillerKCameronMWoodLDalakasMKovacsJ.Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med.2000;133: 192–196.
31.
Medwatch: the FDA safety information and adverse drug event reporting program.Safety-related drug labeling change summaries approved by FDA Center for Drug Evaluation and Research. http://www.fda.gov/medwatch/SAFETY/2002/feb02.htm#zerit. Accessed October 22, 2008.
MartinezEBlancoJLArnaizJAHepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS.2000;15: 1261–1268.
34.
SanneIMommeja-MarinHHinkleJSevere hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis.2005;191: 825–829.
35.
Medwatch: the FDA safety information and adverse drug event reporting program. Safety-related drug labeling change summaries approved by FDA Center for Drug Evaluation and Research. http://www.fda.gov/medwatch/safety/2000/nov00.htm#viramune. Accessed October 22, 2008.
36.
de RequenaDGNúnezMJiménez-NácherISorianoV.Liver toxicity caused by nevirapine. AIDS.2002;16(2):290–291.
37.
SpenglerULichterfeldMRockstrohJK. Antiretroviral drug toxicity—a challenge for the hepatologist?J Hepatol.2002;36(2):283–294.
38.
HaubenMReichL.Safety related drug-labelling changes: findings from two data mining algorithms. Drug Saf.2004;27: 735–744.
39.
HaubenMReichL.Drug-induced pancreatitis: lessons in data mining. Br J Clin Pharmacol.2004;58: 560–562.
40.
HopstadiusJNorenGNBateAEdwardsIR. Impact of stratification on adverse drug reaction surveillance. Drug Saf.2008;31: 1035–1048.
41.
EvansSJW. Stratification for spontaneous report databases. Drug Saf.2008;31: 1049–1052.
42.
van PuijenbroekEPBateALeufkensHGMLindquistMOrreREgbertsACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf.2002;11(1): 3–10.
43.
HaubenMPatadiaVGerritsCWalshLReichL.Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf.2005;28: 835–842.
44.
AlmenoffJTonningJMGouldALPerspectives on the use of data mining in pharmacovigilance. Drug Saf.2005;28: 981–1007.
